These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 21118657)

  • 1. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.
    Dean O; Giorlando F; Berk M
    J Psychiatry Neurosci; 2011 Mar; 36(2):78-86. PubMed ID: 21118657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects.
    Minarini A; Ferrari S; Galletti M; Giambalvo N; Perrone D; Rioli G; Galeazzi GM
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):279-292. PubMed ID: 27766914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of N-acetylcysteine in neuropsychiatry.
    Berk M; Malhi GS; Gray LJ; Dean OM
    Trends Pharmacol Sci; 2013 Mar; 34(3):167-77. PubMed ID: 23369637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.
    Deepmala ; Slattery J; Kumar N; Delhey L; Berk M; Dean O; Spielholz C; Frye R
    Neurosci Biobehav Rev; 2015 Aug; 55():294-321. PubMed ID: 25957927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.
    Bavarsad Shahripour R; Harrigan MR; Alexandrov AV
    Brain Behav; 2014 Mar; 4(2):108-22. PubMed ID: 24683506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine as a new prominent approach for treating psychiatric disorders.
    Smaga I; Frankowska M; Filip M
    Br J Pharmacol; 2021 Jul; 178(13):2569-2594. PubMed ID: 33760228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of cognitive function in schizophrenia with
    Yolland COB; Phillipou A; Castle DJ; Neill E; Hughes ME; Galletly C; Smith ZM; Francis PS; Dean OM; Sarris J; Siskind D; Harris AWF; Rossell SL
    Nutr Neurosci; 2020 Feb; 23(2):139-148. PubMed ID: 29847303
    [No Abstract]   [Full Text] [Related]  

  • 8. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence.
    Ooi SL; Green R; Pak SC
    Biomed Res Int; 2018; 2018():2469486. PubMed ID: 30426004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of N-acetylcysteine in the treatment of schizophrenia].
    Miyake N; Miyamoto S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Apr; 36(2):29-35. PubMed ID: 27333656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility.
    Dodd S; Dean O; Copolov DL; Malhi GS; Berk M
    Expert Opin Biol Ther; 2008 Dec; 8(12):1955-62. PubMed ID: 18990082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The application of N-acetylcysteine in optimization of specific pharmacological therapies].
    Hołyńska-Iwan I; Wróblewski M; Olszewska-Słonina D; Tyrakowski T
    Pol Merkur Lekarski; 2017 Sep; 43(255):140-144. PubMed ID: 28987048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
    Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
    [No Abstract]   [Full Text] [Related]  

  • 13. The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders.
    Bradlow RCJ; Berk M; Kalivas PW; Back SE; Kanaan RA
    CNS Drugs; 2022 May; 36(5):451-482. PubMed ID: 35316513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetylcysteine Reverses Anxiety and Oxidative Damage Induced by Unpredictable Chronic Stress in Zebrafish.
    Mocelin R; Marcon M; D'ambros S; Mattos J; Sachett A; Siebel AM; Herrmann AP; Piato A
    Mol Neurobiol; 2019 Feb; 56(2):1188-1195. PubMed ID: 29876880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine in the treatment of compulsive sexual behavior disorder: A case series.
    Blum AW; Grant JE
    J Psychiatr Res; 2022 Oct; 154():203-206. PubMed ID: 35952519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial.
    Bloch MH; Panza KE; Yaffa A; Alvarenga PG; Jakubovski E; Mulqueen JM; Landeros-Weisenberger A; Leckman JF
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):327-34. PubMed ID: 27027204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review.
    Smith L; Tracy DK; Giaroli G
    J Clin Psychopharmacol; 2016 Feb; 36(1):57-62. PubMed ID: 26629962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
    Rushworth GF; Megson IL
    Pharmacol Ther; 2014 Feb; 141(2):150-9. PubMed ID: 24080471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A minireview on N-acetylcysteine: An old drug with new approaches.
    Elbini Dhouib I; Jallouli M; Annabi A; Gharbi N; Elfazaa S; Lasram MM
    Life Sci; 2016 Apr; 151():359-363. PubMed ID: 26946308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of N-acetylcysteine in the management of substance use disorders.
    McClure EA; Gipson CD; Malcolm RJ; Kalivas PW; Gray KM
    CNS Drugs; 2014 Feb; 28(2):95-106. PubMed ID: 24442756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.